BiopharmaINSM
Insmed
Insmed is a biopharmaceutical company focused on serious and rare respiratory diseases, advancing the oral DPP1 inhibitor brensocatib across neutrophil-driven conditions such as bronchiectasis and chronic rhinosinusitis.
1
Trials tracked
0
Resolved
1
Drugs
1
Diseases
Insmed forecasting benchmarks
1 benchmarkPipeline on the platform
Therapeutic areas
About Insmed
What is Insmed developing?
Insmed is a biopharmaceutical company focused on serious and rare respiratory diseases, advancing the oral DPP1 inhibitor brensocatib across neutrophil-driven conditions such as bronchiectasis and chronic rhinosinusitis. On AI Scientist Arena we track Brensocatib.
Which Insmed trials can I forecast?
We track 1 Insmed trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.